One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Management of dysplastic nevi: a 6 year follow-up survey assessing practice trends among US dermatologists
Nicholas Brownstone, Danny Zakria & Darrell Rigel
doi : 10.1080/09546634.2022.2089324
Journal of Dermatological Treatment, Volume 34, Issue 1 (2023)
Pemphigus foliaceus treated with minocycline monotherapy or low-dose prednisolone combination therapy
Birao Fan, Xixue Chen, Xuejun Zhu & Mingyue Wang
Progressive mucinous histiocytosis treated successfully with thalidomide: a rare case report
Reem Diab, Mohammad Shahidi Dadras, Azadeh Rakhshan, Ali Kaddah & Fahimeh Abdollahimajd
doi : 10.1080/09546634.2022.2117538
Hereditary progressive mucinous histiocytosis (HPMH) is an extremely rare progressive non-Langerhans cell histiocytic disorder presenting with only cutaneous manifestations. Patients typically present with multiple asymptomatic dome-shaped erythematous papules, usually involving the face and upper extremities.
Cannabinoids in hyperhidrosis
Till Kaemmerer, Benjamin Maximilian Clanner-Engelshofen, Tony Lesmeister, Lars Einar French & Markus Reinholz
doi : 10.1080/09546634.2022.2127308
Hyperhidrosis can significantly curtail patient quality of life, from debilitating physical symptoms to social stigmatization and reduced life opportunities. Current treatments often prove unsatisfactory, especially in sufferers of generalized hyperhidrosis.
Topical prebiotics/postbiotics and PRURISCORE validation in atopic dermatitis. International study of 396 patients
Carlo Gelmetti, Corinna Rigoni, Alessandra Maria Cantù, The members of the Italian Groupb (in alphabetical order):, Antonina Agolzer, Alice Agrusa, Michela Brena, Federica Dall’Oglio,
doi : 10.1080/09546634.2022.2131703
Aim: To investigate the efficacy and tolerability of a cream (Rilastil Xerolact PB) containing a mixture of prebiotics and postbiotics, and to validate the PRURISCORE itch scale in the management of atopic dermatitis.
Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
Cathrine Dawn Büttner Elgaard, Lars Iversen & Kasper Fjellhaugen Hjuler
doi : 10.1080/09546634.2022.2133531
Clinical trials have shown promising results for interleukin-23 inhibitors in the treatment of psoriasis. The drugs have been used in clinical practice since 2017.
Efficacy and safety of topical treatments for seborrheic keratoses: a systematic review
Nicole Natarelli, Amanda Krenitsky, Kerry Hennessy, Sarah Moore & James Grichnik
doi : 10.1080/09546634.2022.2133532
Seborrheic keratoses (SKs) are benign epidermal neoplasms presenting as waxy, brown to black papules and plaques. Patients often seek removal for cosmetic reasons or irritation. The objective of this systematic review is to assess the efficacy and safety of topical treatments for SKs.
Systematic review of TNFα-induced paradoxical psoriasis: Treatment outcomes of switching to alternative biologic therapies in inflammatory bowel disease patients
Rishab Revankar, Heli Patel, Mary Rojas, Samantha Walsh & Jean S. McGee
doi : 10.1080/09546634.2022.2133533
The objective of this systematic review was to evaluate the efficacies of different biologic therapies in treating tumor necrosis factor-alpha (TNFα)-induced paradoxical psoriasis (PXP) and controlling inflammatory bowel disease (IBD) symptoms.
Surgical experiences in pediatric pilomatricoma: punch incision and elliptical excision
Hoon Choi, Dong Hyun Shim, Chan Ho Na, Bong Seok Shin & Min Sung Kim
doi : 10.1080/09546634.2022.2133534
As pilomatricoma is a common adnexal skin tumor often occurring in exposed areas, dermatologists focus on minimizing postsurgical scarring.
Are cyclosporine eye drops a suitable treatment in ocular rosacea?
Alvaro Prados-Carmona, Juan J. Prados-Carmona, Marina Gálvez-Moreno & Ricardo Ruiz-Villaverde
doi : 10.1080/09546634.2022.2135964
We would like to congratulate the authors, Samed Magdy Sarsyk and Heba Saed El-Amawy on a thorough literature review [Citation1] that shows not only a comprehensive understanding of dermatological therapies but also the willingness to explore unorthodox alternatives overlapping other tangential areas of Medicine.
Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne
Diane M. Thiboutot, Noah Craft, Robert Rissmann, Ewa Gatlik, Malika Souquières, Julie Jones & Christian Loesche
doi : 10.1080/09546634.2022.2138691
CJM112 is a potent anti-IL-17A monoclonal antibody, whose clinical efficacy in psoriasis was recently documented. This study aimed to assess the effect of IL-17A blockade, using CJM112, in patients with moderate to severe acne.
Use of autologous platelet-rich plasma in androgenetic alopecia in women: a systematic review and meta-analysis
Antonio Flávio Queiroz de Oliveira, Francisco Plácido Nogueira Arcanjo, Maria Rosineida Paiva Rodrigues, Ana Augusta Rosa e Silva & Peter Richard Hall
doi : 10.1080/09546634.2022.2138692
To conduct a systematic review and meta-analysis to verify the efficacy of using autologous platelet-rich plasma (PRP) in female pattern alopecia (FPA).
Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis
Rachel C. Ruda, Katherine A. Kelly & Steven R. Feldman
doi : 10.1080/09546634.2022.2140569
Tumor necrosis factor (TNF) inhibitors improved clinical outcomes for patients with psoriasis but are limited by their high cost. There are several biosimilar options approved for the treatment of psoriasis which provides a lower-cost alternative and the potential to increase treatment availability for both biologically naïve and bioexperienced patients.
A comprehensive review of platelet-rich plasma for the treatment of dermatologic disorders
Jessica N. Pixley, Madison K. Cook, Rohan Singh, Jorge Larrondo & Amy J. McMichael
doi : 10.1080/09546634.2022.2142035
Platelet-rich plasma (PRP) offers anti-inflammatory and regenerative properties through angiogenesis, cell differentiation, and proliferation. Although studied in many dermatologic conditions, its efficacy is not well-understood. Our objective is to review the use and effectiveness of PRP for dermatologic conditions.
Preoperative and postoperative evaluation of survivin in peripheral blood of patients with non-melanoma skin cancers. A pilot study
Eleftheria Tampouratzi, Konstantinos Asonitis, John Katsantonis, Kyriakos Talaiporou & Konstantinos Sfaelos
Improvements in acne and skin oiliness with tazarotene 0.045% lotion in patients with oily skin
Emil A. Tanghetti, Joshua A. Zeichner, Michael Gold, Neil Sadick, Fran E. Cook-Bolden, Leon H. Kircik, Linda Stein Gold, Jonathan Weiss, Stephen K. Tyring, James Q. Del Rosso & Eric Guenin
doi : 10.1080/09546634.2022.2147391
Excessive sebum production is a factor in acne development. Tazarotene 0.045% lotion has demonstrated reductions in acne lesions and acne-induced sequelae.
Comparing the odds of reported depression in psoriasis patients on systemic therapy: a cross-sectional analysis of postmarketing data
Samuel Yeroushalmi, Mimi Chung, Erin Bartholomew, Marwa Hakimi & John Koo
doi : 10.1080/09546634.2022.2152272
Patients with psoriasis are more likely to experience depression and suicidality compared to non-psoriatic patients, though systemic therapies have been shown to improve depressive symptoms. It is unclear whether or not biologic or oral agents are more effective at improving such depressive symptoms in psoriasis patients, however.
Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis
L. Mastorino, F. Gelato, P. Quaglino, M. Ortoncelli & S. Ribero
Deucravacitinib in the treatment of psoriasis
Tomás Estevinho, Ana Maria Lé & Tiago Torres
Intralesional cidofovir for the treatment of recalcitrant periungual warts
McKayla Poppens & Jeremy Davis
doi : 10.1080/09546634.2022.2154569
Purpose: Successful treatment of periungual warts presents a clinical challenge, as many are refractory or represent following conventional treatments. The use of destructive therapies, such as cryotherapy, may even cause permanent nail dystrophy.
Intralesional corticosteroid administration in the treatment of keloids: a survey among Dutch dermatologists and plastic surgeons
Qi Yin, Frank B. Niessen, Susan Gibbs, Oren Lapid, Juliette M. I. Louter, Paul P. M. van Zuijlen & Albert Wolkerstorfer
doi : 10.1080/09546634.2022.2159308
Intralesional corticosteroid administration (ICA) is a first-line therapy in keloid treatment. However, its clinical results are still highly variable and often suboptimal. Treatment results may strongly be influenced by various ways of ICA.
Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021
Adam Reich, Catherine Reed, Christopher Schuster, Camille Robert, Tamas Treuer & Ennio Lubrano
doi : 10.1080/09546634.2022.2160196
To describe the results of a structured literature review of real-world outcomes with ixekizumab in patients with psoriasis (PsO) and/or psoriatic arthritis (PsA).
Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: a cross-sectional cohort study (PsoCOVID)
Kevin V. Kwee, Jean-Luc Murk, Qiqi Yin, M. Birgitte Visch, Linda Davidson, Elke M. G. J. de Jong, Juul M. P. A. van den Reek & Milan Tjioe
doi : 10.1080/09546634.2022.2161297
The risk of SARS-CoV-2 infection does not appear to be increased for psoriasis patients using biologics compared to those on other treatments, but evidence is still limited.
Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials
Thomas Bieber, Norito Katoh, Eric L. Simpson, Marjolein de Bruin-Weller, Diamant Thaçi, Antonio Torrelo, Angelina Sontag, Susanne Grond, Maher Issa, Xiaoyu Lu, Tracy Cardillo, Katrin Holzwarth & Jacob P. Thyssen
doi : 10.1080/09546634.2022.2161812
Baricitinib, a selective Janus kinase (JAK)1/JAK2 inhibitor, is approved for treatment of moderate-to-severe atopic dermatitis (AD) in adults.
The landscape of vitiligo in Latin America: a call to action
Angela Londoño-Garcia, Andrea Arango Salgado, MarÃa de la Luz Orozco- Covarrubias, Angela Marie Jansen, Mariana Rico-Restrepo, MarÃa Cecilia Riviti, Margarita MarÃa Velásquez-Lopera & Carla Castro
doi : 10.1080/09546634.2022.2164171
Vitiligo is a chronic pigmentary condition and severely impacts patient quality of life (QoL). It is an underrecognized burden for patients, healthcare systems, and society in Latin America (LA).
Low irritation potential of tazarotene 0.045% lotion: Head-to-head comparison to adapalene 0.3% gel and trifarotene 0.005% cream in two studies
Zoe D. Draelos
doi : 10.1080/09546634.2023.2166346
Irritation with topical retinoids presents a significant impediment to acne treatment adherence. Two studies assessed the irritation potential of tazarotene 0.045% lotion versus adapalene 0.3% gel and trifarotene 0.005% cream.
Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review
Paolo Gisondi, David Simon, Ivette Alarcon, Effie Pournara & LluÃs Puig
doi : 10.1080/09546634.2023.2167487
Purpose: There is a paucity of evidence on the impact of immune-mediated inflammatory disease (IMID) treatments on the immunogenicity of SARS-CoV-2 vaccination. The purpose of this literature review is to address the question of whether patients with IMIDs receiving secukinumab, a fully human anti–interleukin-17A monoclonal antibody, have an adequate immune response after SARS-CoV-2 vaccination.
Successful treatment of hereditary hypotrichosis simplex by platelet rich plasma injection with topical minoxidil 2%
Wafaa M. Ramadan, Arwa M. Hassan, Esraa E. El-Hawary & Nesrin S. Gomaa
doi : 10.1080/09546634.2023.2169575
Background: Hereditary hypotrichosis simplex is a rare genetic hair disease that affects the scalp. Failure to grow normal hair in terms of length and density is the main complaint of patients. Diagnosis usually established by exclusion of other congenital hair and other ectodermal disorders. Till now, no satisfactory treatment was used for the condition.
Efficacy and safety of stromal vascular fraction on scar revision surgery: a prospective study
Hyeokjae Kwon, Seokui Lee, Jiyoung Kim & Seung Han Song
doi : 10.1080/09546634.2023.2171260
Cell-based therapies are popular in the field of reconstructive surgery. The stromal vascular fraction (SVF), comprised of mature adipocytes or blood, reportedly has a regenerative effect; however the mechanism remains unclear. This study aimed to prove the viability and effectiveness of using SVF in scar treatment.
Granulomatous cheilitis � is there a role for allergen screening and avoidance?
Jessica A. Kern, Amir A. Amanullah, Dev R. Sahni, Jason G. Mathis, Christopher M. Hull, Douglas L. Powell & Aaron M. Secrest
Does hospitalization, independent of other treatment, improve severe chronic skin conditions?
Diem-Phuong D. Dao, Caitlin G. Purvis & Steven R. Feldman
When should systemic biologic therapy for psoriasis be discontinued?
Diem-Phuong D. Dao, Jessica N. Pixley & Steven R. Feldman
Silicone-induced granulomas successfully treated with adalimumab
Francisco Javier de la Torre Gomar, Javier Gimeno Castillo, Pau Rosés Gibert, Erika Iglesias MartÃnez & Maria Isabel MartÃnez González
Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies
Sydney Thai, Joe Zhuo, Yichen Zhong, Qian Xia, Xiu Chen, Ying Bao, Devender Dhanda, Lawshia Priya & Jashin J. Wu
doi : 10.1080/09546634.2023.2176708
Psoriasis is a chronic, immune-mediated, systemic inflammatory disorder associated with high costs. This study evaluated real-world treatment patterns and associated costs in patients in the United States with psoriasis initiating systemic oral or biologic treatments.
Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis
Jashin J. Wu, Ching An Wang, Greeta Jobson, David Davidson, Samaneh Kalirai, Julia Zhu, Manasi Suryavanshi, Mayank Mittal, Vardhaman Patel & Lauren Seigel
doi : 10.1080/09546634.2023.2177095
This study aimed to compare treatment patterns and healthcare costs for patients with psoriasis who initiate apremilast, tumor necrosis factor inhibitor, or interleukin inhibitor.
Intramuscular ertapenem for the treatment of severe cases hidradenitis suppurativa
Juan M. Segura Palacios, Alberto Soto Moreno, Ismael Valladares Millán, Francisco Rivas Ruiz, Carlos Cuenca Barrales & Alejandro Molina Leyva
Development of a new classification and scoring system for scalp conditions: Scalp Photographic Index (SPI)
Bo Ri Kim, Seung Hyun Won, Jee Woo Kim, Minjae Kim, Jeong-Il Jeong, Jung- Won Shin, Chang-Hun Huh & Jung-Im Na
doi : 10.1080/09546634.2023.2181655
There has been no validated tool for objectively quantifying the overall condition and characteristics of the scalp. This study aimed to establish and validate a new classification and scoring system for evaluating scalp conditions.
Efficacy of autologous platelet-rich plasma therapy versus topical Minoxidil in men with moderate androgenetic alopecia: a randomized open-label trial
Mithinkumar Balasundaram, Rashmi Kumari & Sivaranjini Ramassamy
doi : 10.1080/09546634.2023.2182618
Platelet-rich plasma (PRP) is an adjunctive treatment in androgenetic alopecia (AGA). Its role as a monotherapy, when compared to FDA-approved therapies in moderate grades of androgenetic alopecia is not established.
Exacerbation of psoriasis induced by lenalidomide in a patient with multiple myeloma
Guido Mioso, Laura Gnesotto, Irene Russo, Stefano Piaserico & Mauro Alaibac
Efficacity of dupilumab in severe idiopathic cold urticaria: a case report
Valentine Marchal & Ziad Reguiai
Upadacitinib for the treatment of concomitant psoriasis and atopic dermatitis: a case series
Luigi Gargiulo, Luciano Ibba, Giulia Pavia, Jessica Avagliano, Andrea Cortese, Antonio Costanzo & Alessandra Narcisi
doi : 10.1080/09546634.2023.2183729
Purpose: The overlap of psoriasis and atopic dermatitis (AD) is rare and treating moderate-to-severe cases can be challenging. Conventional immune-suppressive drugs cannot be used long-term, and no biological drugs are currently approved for treating both conditions.
Effectiveness and patient satisfaction of a Dutch patient decision aid for psoriasis – a pilot study
A. M. van Huizen, N. J. Rietbergen, G. E. van der Kraaij, D. T. Ubbink & Ph. I. Spuls
Treatment of generalized granuloma annulare with dupilumab
Xiaoting Song, Zirui Chen, Zuotao Zhao & Aiping Wang
Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
L.S. van der Schoot, J.J. Janssen, M.T. Bastiaens, A. de Boer-Brand, C. Christiaansen-Smit, D.N.H. Enomoto, R. Hovingh, R.A. Tupker, M.M.B. Seyger, L.M. Verhoef, J.M.P.A. van den Reek & E.M.G.J. de Jong
doi : 10.1080/09546634.2023.2186728
Dose reduction (DR) of adalimumab, etanercept and ustekinumab has proven to be (cost-)effective in psoriasis patients with low disease activity. Further implementation is needed to establish application of DR for eligible patients.
A new hope in the treatment of onychogryphosis due to acquired malalignment of great toenails: intramatrix dexpanthenol injection
Ömer Kutlu, Uwe Wollina & Fatih Göktay
Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial
Jacob P. Thyssen, Thomas Werfel, Sebastien Barbarot, Hamish J.A Hunter, Evangeline Pierce, Luna Sun, Lisa Cirri, Andrew S. Buchanan, Na Lu & Andreas Wollenberg
doi : 10.1080/09546634.2023.2190430
Patients who completed the originating studies, BREEZE-AD1 (NCT03334396), BREEZE-AD2(NCT03334422), and BREEZE-AD7 (NCT03733301), were eligible for enrollment in the multicenter,phase-3, long-term extension study BREEZE-AD3 (NCT03334435).
Years of dermatology experience and geographic region are associated with outlier performance of excision or destruction for nonmelanoma skin cancer
Brad R. Woodie, Scott A. Neltner, Annabella G. Pauley & Alan B. Fleischer Jr
doi : 10.1080/09546634.2023.2192839
Treatments for nonmelanoma skin cancer (NMSC) include excision (surgical removal) and destruction (cryotherapy or curettage with or without electrodesiccation) in addition to other methods. Although cure rates are similar between excision and destruction for low-risk NMSCs, excision is substantially more expensive.
Dupilumab for the treatment of atopic dermatitis of the elderly: a real-life 52-week experience
Luigi Gargiulo, Francesco Piscazzi, Luciano Ibba, Mario Valenti, Paola Facheris, Chiara Perugini, Antonio Costanzo & Alessandra Narcisi
High-risk squamous cell carcinoma, a surgical challenge: the other face of the SARS-CoV-2 pandemic
Alvaro Prados-Carmona, José MarÃa Llamas-Molina, Pablo Velasco-Amador, Ricardo Ruiz-Villaverde & José Carlos Ruiz-Carrascosa
Experiences and coping behaviors of patients with psoriasis: a qualitative study
Lin-Lin Lee, An-Ping Huo & Shu-Ling Chen
doi : 10.1080/09546634.2023.2193661
Psoriasis is a complex, chronic, lifelong inflammatory skin disease characterized by the development of erythematous, indurated, scaly, pruritic, and often painful skin plaques, and it is currently incurable.
New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series
Luigi Gargiulo, Luciano Ibba, Carlo A. Vignoli, Francesco Piscazzi, Andrea Cortese, Giovanni Fiorillo, Francesco Toso, Giulia Pavia, Mario Valenti, Jessica Avagliano, Alessandra Narcisi & Antonio Costanzo
Long-term management of pediatric psoriasis with ixekizumab: a case report
Diego Orsini, Luciano Ibba, Alessandra Narcisi, Pasquale Frascione, Alessia Pacifico, Mario Valenti, Antonio Costanzo & Luigi Gargiulo
doi : 10.1080/09546634.2023.2198622
Psoriasis in pediatric patients is uncommon and the management of moderate-to-severe cases can be challenging. We report the case of a 17-year-old girl who presented with severe plaque psoriasis unresponsive to UVB phototherapy.
Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials
Yuanyuan Qiu, Yang Zhu, Yun Liu & Qiliang Liu
doi : 10.1080/09546634.2023.2199106
This study aimed to evaluate the efficacy and safety of bimekizumab for psoriasis.
Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study
Luciano Ibba, Luigi Gargiulo, Angela Alfano, Ruggero Cascio Ingurgio, Alessandra Narcisi, Antonio Costanzo & Mario Valenti
